 Shares of Madrigal Pharmaceuticals Inc. soared 209.6 in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 clinical trial assessing its experimental treatment for nonalcoholic steatohepatitis NASH with liver fibrosis. Madrigal said it is aiming to get an accelerated approval for the drug, resmetirom. There are no approved treatments ... The post Madrigals stock rallies about 200 after sharing positive data about its NASH treatment candidate appeared fi... 